Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
#5PRI RANKED
Most Cited Paper
in Monoclonal and Polyclonal Antibodies Research
18 Months Post-Publication
Class of 2026
“Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026/
Topics
Mosunetuzumab · CD20-targeted therapy · T-cell-engaging bispecific antibody · Relapsed/refractory follicular lymphoma · Fixed-duration treatment · Complete response rate · Objective response rate · Duration of response · Progression-free survival · Overall survival · CD19+ B-cell recovery · cytokine release syndrome · Off-the-shelf therapy · Outpatient administration · High-risk disease · Phase I/II trial · NCT02500407 · Long-term follow-up safety · T-cell-engaging bispecific antibody · ≥2 prior lines of therapy
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026. Accessed 2026-07-15. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459